Flucelvax
INFLUENZA A VIRUS A/Georgia/12/2022 CVR-167 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA A VIRUS A/Victoria/800/2024 CVR-289 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA B VIRUS B/Singapore/WUH4618/2021 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED)
Listed by Bamboo US BidCo LLC
- Strength
- 15 ug/.5mL, 15 ug/.5mL, 15 ug/.5mL
- Form
- Injection, Suspension
- Route
- Intramuscular
What it contains
- Influenza A Virus A/georgia/12/2022 Cvr-167 (h1n1) Antigen (mdck Cell Derived, Propiolactone Inactivated) 15 ug/.5mL
- Influenza A Virus A/victoria/800/2024 Cvr-289 (h3n2) Antigen (mdck Cell Derived, Propiolactone Inactivated) 15 ug/.5mL
- Influenza B Virus B/singapore/wuh4618/2021 Antigen (mdck Cell Derived, Propiolactone Inactivated) 15 ug/.5mL
This is a combination product. It is not interchangeable with a single-ingredient medicine containing only one of these.
FDA record
| Dosage form | Injection, Suspension |
|---|---|
| Route | Intramuscular |
| Approval route | BLA — biologic licence |
| NDC code | 83703-088 |
| FDA application | BLA125408 |
| Package sizes listed | 1 |
| Marketed since | August 2026 |
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.